Ruti Aga and the Six-Year Ledger: Two Years for the Drug, Four for the Prescription That Never Existed

The prescription had a drug name on it. It had a doctor's name. It had a clinic address. The Athletics Integrity Unit checked all three separately. No clinic existed at that address. The man who called himself a doctor was a member of Aga's family and his name was on no medical register. And the "old prescription pad" he cited was disowned outright by the hospital he claimed to have worked at.

Three claims. Three checks. Three failures. And the price of them is six years.

Two years for the drug, methylprednisolone. Four years for the paper that was manufactured to make the drug look legitimate. 2 + 4 = 6. Everything worth understanding about this case begins with that sum — not with the weeping, not with national sympathy, and not with the ready-made frame about discrimination against African athletes.

Ruti Aga, 32, Ethiopia, marathon. The ban was counted from 10 September — the same date her provisional suspension began. It starts at 32 and ends at 38. There is no room in Ethiopian women's marathoning for a 38-year-old returning athlete, and certainly none for one with a doping record. On paper this is a six-year sanction. In career terms it is a lifetime one.

I opened this file at two in the morning and the numbers started talking. The file was stamped 2 a.m.; the truth arrived later. What arrived first was the realisation that this is not a performance story. There is no time in it, no split, no field strength. The only performance fact is that she won a half marathon in China in March. She won it — which is why a sample exists. That is all.

When the sample was taken is itself a technical question

The testing window in road racing is not the one that applies on a stadium track. Under World Athletics rules, the in-competition period for a road race opens at 23:59 the night before the race. So if an athlete takes a knee injection three or four days out and residue is still detectable on race day, that is a straightforward in-competition violation. To the outside world this is a footnote. To the athlete and her physio it is the entire case.

Aga won a half marathon in China in March. The name of the race is not in the public statement, nor is the time, nor the prize money. The AIU statement came on Thursday and said only that the sample was positive. Under standard AIU practice, the result and prize money from the race where the sample was collected are automatically annulled — the statement does not say so, but that is the practice. The figures in my file come from external sources and I am still verifying them: 2:18:34 for second in Berlin 2026, 2:20:40 for the win in Tokyo 2026. No personal-best improvement is recorded after that. That data is pending, so I am treating it as context, not conclusion.

The question is not how fast she was. The question is what economic model a 2:18–2:20 marathoner runs on. The answer is clear: few races, large appearance fees, and Asia's label-race circuit in between the Majors. China's half marathon circuit is the fattest part of that model — big budgets, deep East African elite fields, and now the most closely watched territory of all. The appearance-fee economy and the testing economy are colliding in the same races.

The classification: where the reporting went wrong

A correction is necessary here, and it is not word-policing. Several reports described methylprednisolone as a "prohibited steroid" and said WADA classes it as performance-enhancing. That is incomplete and misleading. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List, not an anabolic steroid (S1). Under the current List, S9 glucocorticoids are prohibited in-competition only, by injection, oral or rectal route.

That single correction changes the entire case, because this was never a case about the drug — it was a case about route and timing. A therapeutic knee injection out of competition is entirely legal. It becomes a violation only if residue is present in competition. Aga therefore had a genuine defence available: date, route, and a documented medical need. She did not keep that defence alive. She replaced it with a forged document.

Fake paperwork costs more than real illness, every single time. If the knee treatment genuinely happened and the records genuinely existed, the case travels to a therapeutic use exemption, or at worst lands in the no-significant-fault band and shrinks the sanction substantially. What happened is the inverse.

Three checks on the prescription, and why all three failed

The heaviest part of the AIU statement is not the drug. It is the paper. The clinic did not exist. The "doctor" held no medical registration. The prescription pad was disowned by the hospital it was attributed to. Three independent verification failures — this is not the level of carelessness, this is a document somebody set out to manufacture and somebody else passed along unexamined.

The four-year tampering sanction does not come from a document alone. It comes from an interview — from statements made under questioning. Language and translation conditions in AIU interviews with East African athletes have been a recurring point of contention, and they will be raised here too. But one distinction cannot be waved away: a language problem does not conjure a clinic into existence.

What makes this case rare is that the athlete destroyed her own strongest defence. The two years are for the presence violation — the substance was in her body, intent was not proven. That is the ordinary sanction for what the Code calls a specified substance. The four years are the Code's standard tampering sanction. The sum tells us the panel rejected the no-significant-fault mitigation — because no athlete who commissions a fake prescription can claim innocent carelessness.

The arithmetic of two and four

The architecture of the sanction is standard, not exceptional. It can be read three ways.

First, had Aga possessed genuine medical records and a clean route-and-timing explanation, the presence charge could have been argued at the no-fault or no-significant-fault end — a reprimand or a much shorter period, and no tampering charge at all. Second, had a TUE-consistent treatment plan been followed with correct washout timing, there would have been no case whatsoever. Third, what actually happened: six years, and a likely wipeout of results.

Backdating to 10 September is not relief. Time served under provisional suspension counts against the ban, so the athlete gains nothing in real terms. It is a procedural convenience, not a discount.

The age line, and Ethiopian depth

Thirty-two in the marathon means late peak or the beginning of decline. Six years later, 38. To imagine a comeback at 38 in Ethiopian women's marathoning you have to forget that a sub-2:16 performer there cannot even treat national selection as a formality. The women's marathon world record has already gone below 2:12. A 2:18–2:20 athlete is very good in that country and not good enough to be picked.

So this ban has a zero effect on Ethiopia's medal capacity. Aga's record includes three second-place finishes at World Marathon Majors — commercial-tier results, not championship conversions. When an athlete comes from the deepest marathon nation on earth and holds no global championship medal, her removal does not change a single line in the selection maths.

Here I have to stop one of my own reflexes. In 2026, from the tribune at Kalinga Stadium in Bhubaneswar, I sorted 40 Indian javelin personal bests by district — Panipat, Karnal, Sangrur, Ludhiana, repeating. That sheet taught me that the map of strength is drawn by infrastructure and money, never by population. Applying the same formula to Ethiopian marathoning would be a mistake: there the pipeline is run by agents and camps, not federations. Where India has NIS Patiala and the Railways quota system, Ethiopia has agent-run training clusters. The difference is this: in one place the state pays the physio, in the other the agent does — and often nobody does.

The funding line: who pays the doctor

Aga commissioned the prescription. That is her act and she pays for it. But it is not alright to stop asking why she needed to commission one. The answer is in the money.

A credentialed team physician is expensive. A marathoner's income runs on appearance fees, prize money and thin sponsorship. Running through persistent knee pain means stopping, and stopping means the fees stop. A glucocorticoid is the cheapest, most available and fastest form of relief. Where there is no physician, someone who will write a prescription always turns up — sometimes in a clinic, sometimes in the family.

I keep a tracker from 2026: 217 Indian track and field athletes with no competition date and no qualifying window that year. Between Guwahati and Patiala, the calendar went quiet. In that tracker was a Railways sports-quota 800m runner whose salary continued while her season vanished. That tracker taught me that the question in Indian athletics is not who won, it is whose salary is running. The same question should be asked in Ethiopia, only the answer will be in an agent's contract rather than a railway board's ledger.

The system that pushed an athlete toward a prescription with three verification failures in it receives no sanction. Only the athlete does. That is the most uncomfortable line in this case, and I know, writing it, that it can be used to dodge accountability. So let me be explicit: accountability runs both ways. She signed the paper. Nobody funded the physician.

China's label circuit and the new front line

The March race was in China and that is no coincidence. China's label race circuit pays large appearance fees, pulls deep East African elite fields, and is now the AIU's most productive testing ground. Where the money is dense and the athletes are foreign, the testing is dense too.

A pattern is visible here that should be read not from this case alone but from the cluster around it. The East African road-racing cases in which a substance violation is followed by a fabricated or altered explanation look like one family. The enforcement frontier has shifted from detection to document verification. And once investigation centres on documents, the sanction is decided not by the drug but by the quality of the paperwork.

The contrarian question: six years for what, exactly

Here I want to stand against my own story.

Methylprednisolone is a drug with no proven performance-enhancing benefit for endurance. It reduces inflammation, reduces pain, and makes an athlete fit to race — that is a real advantage, but it is the same advantage any painkiller offers. Comparing it to anabolic steroid cases is technically wrong, and the reports calling it a "steroid" are making that wrong comparison worse.

So what are six years for? The plain answer: the paper. Four of those years are not for the drug but for the cover story built around it. And that raises an uncomfortable question which makes this bigger than one athlete's mistake.

An athlete travelling with a credentialed physician and a lawyer builds a defence out of documents. An athlete travelling alone builds one out of a scrap of paper — and that scrap puts her away for six years. Severity of sanction is being set by something this sport never discusses: the entourage budget.

I have to write this too: the argument does not excuse the sanction. Manufacturing a fake medical document is serious, because it defrauds the system built to protect clean athletes. But when four of six years are decided by the quality of paper, it is hard to believe we are only fighting a drug.

What to watch next

My habit is to write the scenario before the result and grade myself after. Here is a scenario tree with three named conditions and dates.

Condition one: appeal. A reasoned decision normally opens a CAS appeal window of roughly 21 days. If an appeal is filed and the document-based finding holds, six years stands. Document findings are hard to overturn because there is no argument in them, only verification.

Condition two: the scope of disqualification. The statement does not specify which results were annulled. The March race result and its prize money are the likeliest casualties. The 2026 Tokyo title predates that date and is not automatically void absent evidence of earlier use. If the AIU ever reaches back before 2026, this becomes an entirely different case.

Condition three: the federation's silence. No statement has come from the Ethiopian federation. That silence is itself news, because the question is what that country's system is doing to give its athletes credentialed medical support. If the answer is only that an investigation is ongoing, the next case will come out of the same file.

I am adding one more line to this file, and it is not about 0.01 seconds. It is that the biggest lesson here is not about a drug but about a receipt. The day an athlete holds a physio's invoice, a doctor's name and a TUE document, she will not need to commission a prescription — and the argument over whose six years these were, the drug's or the paper's or the system's that left her alone, will finally be over.